|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hinweise |
|
|
|
Wiss. Komitee |
|
|
|
Adressen |
|
|
|
Presse |
|
|
|
Öffnungszeiten |
|
|
|
Gesellschaften |
|
|
|
Hotelreservierung |
|
|
|
Termine |
|
|
|
Rahmenprogramm |
|
|
|
Gebühren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Online-Anmeldung
Online-Abstracts
Kontakt-Adressen
Congress Center Leipzig
zurück zum Start
Programm-Schwerpunkte-Gesellschaften
|
Symposium 6 HIV-Infektion I |
||
|
15.30 – 17.00 |
Vorsitz F.D. Goebel; München, Th. Harrer; Erlangen |
|
|
Level 1 – Raum 3 |
|
|
|
03.05.2001 |
Sy 06.01 |
Therapiepausen |
|
15.30 |
Sh. Stasczewski; Frankfurt/Main |
|
|
Sy 06.02 |
T-Zell-Immunität bei HIV-Infizierten |
|
|
15.48 |
Th. Harrer; Erlangen |
|
|
Sy 06.03 |
Nachweis multipler Aktivierungszustände von CCR5 mit Hilfe monoklonaler Antikörper und Bedeutung der CCR5-Dimerisierung für die Endozytose von CCR5 |
|
|
16.06 |
M. Mack, J.-M. Vanderwinden*, J. Cihak, V. Wittamer*, E. le Poul*, M. Stangassinger, G. Vassart*, D. Schlöndorff, M. Parmentier*, C. Blanpain*; München und *Brüssel (BE) |
|
|
Sy 06.04 |
Analyse von residueller HIV-Replikation, proviraler HIV-1 DNA und Immunaktivierung in HAART-therapierten Patienten |
|
|
16.24 |
I. Hauber, P. Löw, M. Schmitt, E. Schwingel, J.R. Kalden, J. Hauber, Th. Harrer; Erlangen |
|
|
Sy 06.05 |
Mutationen im HIV-1 Protease-Gen – Bedeutung für die phänotypische Resistenz |
|
|
16.42 |
H. Müller, N. Wiese, H.-G. Maxeiner, U. Schmitz, Th. Fenner; Hamburg |
|
|
|
||